In this Nov. 6, 2019, file photo, Kanye West attends the WSJ. Magazine 2019 Innovator Awards at the Museum of Modern Art in New York. The rap superstar will design adult and kids' clothing that will be sold at Gap in 2021. Yeezy is best known for pricey sneakers that sell out online quickly. But Yeezy footwear, made with sneaker company Adidas, won't be sold at Gap. (Photo by Evan Agostini/Invision/AP, File)
By Joseph Pisani
Kanye West is bringing his Yeezy brand to Gap.
The rap superstar will design adult and kids' clothing that will be sold at the chain's stores next year. Yeezy is best known for pricey sneakers that sell out online quickly. But Yeezy footwear, made with sneaker company Adidas, won't be sold at Gap stores.
San Francisco-based Gap Inc., whose sales are dwindling, hopes the deal will keep it relevant with shoppers. For Yeezy, being in more than 1,100 stores worldwide could get the brand in front of more people.
On Friday, West tweeted a photo of what the collaboration might look like: bright colored hoodies, jackets, and T-shirts.
West has a history with Gap. He worked at one of its stores in Chicago as a teenager. And he told Vanity Fair magazine back in 2015 that he wanted to be creative director of the brand.
As part of the deal announced Friday, Yeezy will receive royalties and possibly Gap stock if the line sells well.
Shares of the retailer jumped 16% in premarket trading.
Jay Hatfield, chief investment officer for ICAP, joined Cheddar News to discuss how markets are reacting to labor market news and what the Federal Reserve will do next in terms of interest rates.
Kristin Cavallari, who first gained fame as a cast member of the MTV reality show Laguna Beach, is now the founder of a beauty company called Uncommon James. Cheddar News anchor Hena Doba took a walk with Cavallari to discuss her many business ventures.
Heardle, the name-that-tune game inspired by the Wordle craze, is being dropped by Spotify less than a year after the music-streaming giant acquired it.
Moderna and Merck & Co. have developed a cancer vaccine that cuts the risk of death or recurrence of most deadly skin cancer by 44 percent compared to Keytruda on its own, according to researchers.
